KR900018043A - 항알레르기제 및 소염제로서 유용한 티아졸리디논, 이미다졸리디논 및 옥사졸리디논의 선택된 신규 아릴메틸레닐 유도체 - Google Patents

항알레르기제 및 소염제로서 유용한 티아졸리디논, 이미다졸리디논 및 옥사졸리디논의 선택된 신규 아릴메틸레닐 유도체 Download PDF

Info

Publication number
KR900018043A
KR900018043A KR1019890007006A KR890007006A KR900018043A KR 900018043 A KR900018043 A KR 900018043A KR 1019890007006 A KR1019890007006 A KR 1019890007006A KR 890007006 A KR890007006 A KR 890007006A KR 900018043 A KR900018043 A KR 900018043A
Authority
KR
South Korea
Prior art keywords
methylene
thioxo
thiazolidinone
hydroxy
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019890007006A
Other languages
English (en)
Other versions
KR970002228B1 (ko
Inventor
앤틴 세텐코 위아체슬러
토마스 코너 데이비드
죠셉 소렌슨 로드릭
챨스 우낭스트 폴
러셀 스테블러 스티븐
Original Assignee
크리스틴 에이.트러트웨인
워너-램버트 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크리스틴 에이.트러트웨인, 워너-램버트 캄파니 filed Critical 크리스틴 에이.트러트웨인
Publication of KR900018043A publication Critical patent/KR900018043A/ko
Application granted granted Critical
Publication of KR970002228B1 publication Critical patent/KR970002228B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

항알레르기제 및 소염제로서 유용한 티아졸리디논, 이미다졸리디논 및 옥사졸리디논의 선택된 신규 아릴메틸레닐 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (75)

  1. 하기 일반식(Ⅰ)의 화합물 및 제약상 허용되는 이들의 염 및 제약상 허용되는 담체로 되는 체약 조성물.
    식중, Ar은 (ⅰ)페닐기, (ⅱ)저급 알킬, 저급 알콕시, 히드록시, 할로겐, 트리플루오로메틸, NO2, 메르캅토 또는 저급 알킬티오 NR10R11기(여기에서, R10및 R11은 독립적으로 수소 또는 저급 알킬기임)중에서 선택되는 1내지 3개의 기로 치환된 페닐기, (ⅲ)나프틸기, (ⅳ)벤조푸라닐기, (ⅴ)벤조티오페닐기, (ⅵ)티에닐기, (ⅶ)인돌릴기, (ⅷ)푸라닐기, (ⅸ)피리딜기이고, Y 및 Y1은산소 원자 또는 황원자이며, X는 황 원자, 산소 원자, NH 또는 NCH3기이고, X1은 NCH3기이되, 단 Ar은 3,5-디(이소프로필)-4-히드록시페닐기가 아니고, 또한 X1=NH, X=S, Y=S이면, Ar은 3,5-디(t-부틸기)-4-히드록시페닐기가 아니다.
  2. 제1항에 있어서, 화합물이 하기 일반식(Ⅱ)의 구조를 갖는 조성물.
    식중, X 및 Y는 상기 정의한 바와 같고, R1, R2, R3, R4, 및 R5중 1내지 3개의 기는 저급 알킬, 저급 알콕시, OH, 할로겐, CF3, NR10R11기(여기서, R10및 R11은 상기 정의한 바와 같음), NO2메르캅토, 또는 저급 알킬티오기 중에서 선택된다.
  3. 제2항에 있어서, 화합물이 하기 일반식(Ⅲ)의 구조를 갖는 조성물.
    식중, R1, R2, R3, R4, 및 R5는 상기 정의한 바와 같다.
  4. 제2항에 있어서, 화합물이 다음 일반식(Ⅳ)의 구조를 갖는 조성물.
    식중, R1, R2, R3, R4, 및 R5는 상기 정의한 바와 같다.
  5. 제2항에 있어서, 화합물이 다음 일반식(Ⅴ)의 구조를 갖는 조성물.
    식중, R1, R2, R3, R4, 및 R5는 상기 정의한 바와 같다.
  6. 제2항에 있어서, 화합물이 다음 일반식(Ⅵ)의 구조를 갖는 조성물.
    식중, R1, R2, R3, R4, 및 R5는 상기 정의한 바와 같다.
  7. 제2항에 있어서, 화합물이 다음 일반식(Ⅶ)의 구조를 갖는 조성물.
    식중, R1, R2, R3, R4, 및 R5는 상기 정의한 바와 같다.
  8. 제2항에 있어서, 화합물이 다음 일반식(Ⅷ)의 구조를 갖는 조성물.
    식중, R1, R2, R3, R4, 및 R5는 상기 정의한 바와 같다.
  9. 제2항에 있어서, 화합물이 다음 일반식(ⅧA)의 구조를 갖는 조성물.
    식중, R1, R2, R3, R4, 및 R5는 상기 정의한 바와 같다.
  10. 제3항에 있어서, 5-[(2,5-디메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논인 조성물.
  11. 제3항에 있어서, 5-[(2,4,5-트리메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논인 조성물.
  12. 제3항에 있어서, 5-[(2,4,5-트리메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논의 모노소듐염인 조성물.
  13. 제3항에 있어서, 5-[(2,4,5-트리메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논인 조성물.
  14. 제3항에 있어서, 5-[(3,4-디클로로페닐)메틸렌]-2-티옥소-4-티아졸리디논인 조성물.
  15. 제3항에 있어서, 5-[(3,4,5-트리메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논의 모노소듐염인 조성물.
  16. 제3항에 있어서, 5-[(3,4-디클로로페닐)메틸렌]-2-티옥소-4-티아졸리디논인 조성물.
  17. 제3항에 있어서, 5-[(3,4-디클로로페닐)메틸렌]-2-티옥소-4-티아졸리디논의 모노소듐염인 조성물.
  18. 제3항에 있어서, 5-[(3,4-디메톡시-4-히드록시페닐)메틸렌]-2-티옥소-4-티아졸리디논인 조성물.
  19. 제3항에 있어서, 5-[(3,4,5-트리메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논의 디소듐염인 조성물.
  20. 제3항에 있어서, 5-[(3,4-디매탈-4-히드록시페닐)메틸렌]-2-티옥소-4-티아졸리디논인 조성물.
  21. 제3항에 있어서, 5-[(3,4-디클로로페닐)메틸렌]-2-티옥소-4-티아졸리디논의 디소듐염인 조성물.
  22. 제3항에 있어서, 5-[(3-브로모-4-히드록시-5-메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논인 조성물.
  23. 제3항에 있어서, 5-[(3,4-디클로로페닐)메틸렌]-2-티옥소-4-티아졸리디논의 디소듐염인 조성물.
  24. 제3항에 있어서, 5-[(4-메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논인 조성물.
  25. 제3항에 있어서, 5-[(3-히드록시-4-메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논인 조성물.
  26. 제3항에 있어서, 5-[(3,4-디클로로페닐)메틸렌]-2-티옥소-4-티아졸리디논인 조성물.
  27. 제3항에 있어서, 하기로 된 군중에서 선택되는 조성물. 5-[(2,3-디메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(2,4-디메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논. 2-티옥소-5-[(2,3,4-트리메톡시페닐)메틸렌]-4-티아졸리디논. 5-[(2,4-디메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논.5-[(3-플루오로-4-메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(3,4-디히드록시페닐)메틸렌]-2-티옥소-4-티아졸리디논.5-[(3-브로모-4-히드록시페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(3,5-브로모-4-히드록시페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(2-메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(3-멕시토페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(3-히드록시페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(4-히드록시페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(3-에톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(3-(메틸에톡시)메틸렌]-2-티옥소-4-티아졸리디논. 2-티옥소-5-[[3-(트리플루오로메틸)페닐)메틸렌]-4-티아졸리디논. 5-[(3-클로로페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(3-브로모페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(3-니트로페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(4-클로로페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(4-브로모페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(4-페녹시페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(4-니트로페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(4-메틸티오페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(4-히드록시-3-메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논 및 그의 디소듐염, 5-[(4-메틸페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(1,1'-비페닐)-4-일메틸렌]-2-티옥소-4-티아졸리디논. 5-[(2,6-디클로로페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(3-클루오로페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(2-히드록시페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(3-히드록시-4.5-디메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(2,6-디멕토시페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(2-히드록시-5-메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(3-히드록시-5-메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논. 5-[(3(1,1-디메틸에틸)-4-히트록시-5-메톡시페닐]메틸렌]-4-티아졸리디논. 5-[(3-디메틸아미노)메틸-4-히드록시-5-메톡시페닐]메틸렌]-2-티옥소-4-티아졸리디논. 및 5-[(2-히드록시-4,5-디메톡시페닐메틸렌]-2-티옥소-4-티아졸리디논.
  28. 제1항에 있어서, 하기로 된 군 중에서 선택되는 조성물. 5-[(5-브로모-2-티에닐)메틸렌]-2-티옥소-4-티아졸리디논, 5-[(5-브로모-2-티에닐)메틸렌]-2-티옥소-4-티아졸리디논의 모노소듐염, 5-[(6-메톡시-2-벤조푸라닐)메틸렌]-2-티옥소-4-티아졸리디논, 5-[(5-메톡시-2-벤조푸라닐)메틸렌]-2-티옥소-4-티아졸리디논, 5-[(벤조(b)티엔-2-일)메틸렌]-2-티옥소-4-티아졸리디논,5-[(5-메톡시-3-1-페닐-1H-일돌-2-일)메틸렌]-2-티옥소-4-티아졸리디논, 5-[(5-메톡시-1-페닐-1H-일돌-2-일)메틸렌]-2-티옥소-4-티아졸리디논,1-메틸피페리딘 염, 5-[(4-피리딜)메틸렌]-2-티옥소-4-티아졸리디논, 5-[(-2-티에닐)메틸렌]-2-티옥소-4-티아졸리디논, 5-[(5-니트로-2-푸라닐)메틸렌]-2-티옥소-4-티아졸리디논 및 5-[(1-페닐-1H-인돌-2-일)메틸렌]-2-티옥소-4-티아졸리디논,
  29. 제4항에 있어서, 5-[(4-히드록시-3,5-디메톡시페닐)메틸렌]-2-티옥소-4-티아졸리딘디온인 조성물.
  30. 제4항에 있어서, 5-[(4-히드록시-3-메톡시페닐)메틸렌]-2,4-티아졸리딘디온인 조성물.
  31. 제4항에 있어서, 하기로 군 중에서 선택되는 조성물. 5-[(3,5-비스(1,1-디메틸에틸)-4-히드록시페닐)메틸렌]-2,4-티아졸리딘디온, 5-[(페닐)메틸렌]-2,4-티아졸리디온, 5-(m-메톡시벤질리덴)-2,4-티아졸리딘디온, 및 5-[(4-메톡시페닐)메틸렌]-2,4-티아졸리딘디온.
  32. 제5항에 있어서, 5-[(4-히드록시-3-메톡시페닐)메틸렌]-2,4-옥사졸리디논인 조성물.
  33. 제5항에 있어서, 5-[(4-히드록시-3,5-디메톡시페닐)메틸렌]-2,4-옥사졸리디논인 및 그의 디소듐염인 조성물.
  34. 제5항에 있어서, 하기로 된 군중에서 선택되는 조성물. 5-[(3-메톡시페닐)메틸렌]-2-티옥소-4-옥사졸리디논인 및 그의 디소듐염. 5-[(4-메톡시페닐)메틸렌]-2-티옥소-4-옥사졸리디논. 5-[(3,4-디메톡시페닐)메틸렌]-2-티옥소-4-옥사졸리디논, 5-[(4-히드록시-3,5-디메톡시페닐)메틸렌]-2-티옥소-4-옥사졸리디논, 5-[(3-브로모-4-히드록실)메틸렌]-2-티옥소-4-옥사졸리디논, 2-티옥소-5-[(2,4,5-트리메톡시페닐)메틸렌]-4-옥사졸리디논, 및 2-티옥소-5-[(3-브로모-4-히드록시페닐)메틸렌]-4-옥사졸리디논.
  35. 제5항에 있어서, 2-티옥소-5-[(3,4,5-트리메톡시페닐)메틸렌]-4-옥사졸리디논인 조성물.
  36. 제6항에 있어서, 5-[(4-히드록시-3,5-디메톡시페닐)메틸렌]-2-티옥소-4-아미다졸리디논인 조성물.
  37. 제6항에 있어서, 하기로 된 군중에서 선택되는 조성물.5-[(3-디브로모-4-히드록시페닐)메틸렌]-2-티옥소-4-이미다졸리디논, 5-[(3-브로모-4-히드록시페닐)메틸렌]-2-티옥소-4-이미다졸리디논, 5-[[3-비스(1,1-디케틸에틸)-4-히드록시페닐)메틸렌]-2-티옥소-4-이미다졸리디논, 5-[2-메톡시페닐)메틸렌]-2-티옥소-4-이미다졸리디논, 5-[(3-메톡시페닐)메틸렌]-2-티오-5-바닐릴리덴-히단토인, 및 5-[(4-히드로톡시-3,5-디메톡시페닐)메틸렌]-2-티옥소-4-이미다졸리디논,
  38. 제7항에 있어서, 하기로 된 군중에서 선택되는 조성물. 5-[(4-(아세틸옥시)-3-메톡시페닐)메티렌]-2,4-이미다졸리딘디온, 5-[(4-히톡시-3-디메톡시페닐)메티렌]-2,4-이미다졸리딘디온, 5-[[3,5-비스(1,1-디메틸에틸)-4-히드록시페닐]-2,4-이미다졸리딘디온, 5-[(3-메톡시페닐)메틸렌]-1-메틸-2,4-이미다졸리딘디온, 5-[[4-히드록시-3-메톡시페닐)메티렌]-1-메틸-2,4-이미다졸리딘디온,5-[[4-히드록시-3,5-디메톡시페닐)메티렌]-1-메틸-2,4-이미다졸리딘디온, 5-[(3,5-디브로도-4-히드록시페닐)메티렌]-1-메틸-2,4-이미다졸리딘디온, 5-[(4-히드록시-3,5-비스(1-메틸에틸)페닐]메티렌]-1-메틸-2,4-이미다졸리딘디온.
  39. 제8항에 있어서, 하기로 된 군중중에서 선택되는 조성물. 5-[(2-메톡시페닐]메틸렌]-3-메틸-2,4-이미다졸리딘디온, 5-[(3-메톡시페닐]메틸렌]-3-메틸-2,4-이미다졸리딘디온, 5-[(4-메톡시페닐]메틸렌]-3-메틸-2,4-이미다졸리딘디온, 3-메틸-5-비닐릴리덴-히단토인 및 5-[(4-히드록시-3,5-디메톡시페닐]메틸렌]-3-메틸-2,4-이미다졸리딘디온.
  40. 제9항에 있어서, 하기로 된 군중에서 선택되는 조성물. 5-[[3,5-비스(1,1-디메틸에틸)-4-히드록시페닐]메틸렌]-2,4-옥사졸리디논, 5-[[4-히드록시-3,5-디메틸에틸)메틸렌]-2,4-옥사졸리디논, 및 5-[(4-히드록시-3,5-디메틸에틸)메틸렌]-2,4-옥사졸리디논.
  41. 항알레르기에 효과적인 양의 제1항에 의한 조성물을 단위 투여량 형태로 투여함을 특징으로 하는 인체의 알레르기 치료 방법.
  42. 소염에 효과적인 양의 제1항에 의한 조성물들을 단위 투여량 형태로 투여함을 특징으로 하는 소염제로서의 사용 방법.
  43. 5-[(3-플루오로-4-메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논.
  44. 5-[(3-브로모-4-히드록시페닐)메틸렌]-2-티옥소-4-티아졸리디논.
  45. 5-[(3-디브로모-4-히드록시페닐)메틸렌]-2-티옥소-4-티아졸리디논.
  46. 5-[(3-브로모-4-히드록시-5-메톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논.
  47. 제42항의 화합물의 디소듐염.
  48. 5-[(3-플루오로페닐)메틸렌]-2-티옥소-4-티아졸리디논.
  49. 5-[(4-히드록시-3-메톡시-5-tert. 부틸페닐)메틸렌]-2-티옥소-4-티아졸리디논.
  50. 5-[2-히드록시-4,5-디멕톡시페닐)메틸렌]-2-티옥소-4-티아졸리디논.
  51. 5-[(3-디메틸아미노)메틸렌]-2-티옥소-4-티아졸리디논.
  52. 5-[(4-히드록시-3,5-디메톡시페닐)메틸렌]-2,4-티아졸리디논.
  53. 5-[(3-멕토시페닐)메틸렌]-2-티옥소-4-옥사졸리디논.
  54. 5-[(3,4-디메톡시페닐)메틸렌]-2-티옥소-4-옥사졸리논.
  55. 5-[(4-히드록시-3,5-디메톡시페닐)메틸렌]-2-티옥소-4-옥사졸리디논.
  56. 5-[(4-히드록시-3,5-디메틸페닐)메틸렌]-2-티옥소-4-옥사졸리디논.
  57. 5-[(3-브로모-4-히드록시-5-메톡시페닐)메틸렌]-2-티옥소-4-옥사졸리디논.
  58. 2-티옥소-5-[(2,4,5-트리메톡시페닐)메틸렌]-4-옥사졸리디논.
  59. 5-[(3,5-디브로모-4-히드록시페닐)메틸렌]-2-티옥소-4-아미다졸리디논.
  60. 5-[(3-브로모-4-히드록시페닐)메틸렌]-2-티옥소-4-이미다졸리디논.
  61. 5-[(3,5-디메톡시-4-히드록시페닐)메틸렌]-2-티옥소-4-이미다졸리디논.
  62. 5-[(3,5-디메톡시-4-히드록시페닐)메틸렌]-3-메틸-2,4-이미다졸리디온.
  63. 5-[(4-히드록시-3-메톡시페닐)메틸렌]-1-메틸-2,4-이미다졸리디온.
  64. 5-[(3,5-디메톡시-4-히드록시페닐)메틸렌]-1-메틸-2,4-이미다졸리디온.
  65. 5-[(3,5-디메톡시-4-히드록시페닐)메틸렌]-1-메틸-2,4-이미다졸리디온.
  66. 5-[(3,5-비스(1,1-디메틸에틸)-4-히드록시페닐)메틸렌]-2,4-티아졸리디인이온.
  67. 5-[(3,5-비스(1,1-디메틸에틸)-4-히드록시페닐)메틸렌]-2-티옥시-4-옥사졸리디논.
  68. 5-[(3,5-비스(1,1-디메틸에틸)-4-히드록시페닐)메틸렌]-2,4-옥사졸리디논.
  69. 5-[(4-히드록시-3,5-디메톡시페닐)메틸렌]-2.4-옥사졸리디딘온.
  70. 5-[(4-히드록시-3,5-디메톡시페닐)메틸렌]-2,4-옥사졸리디논.
  71. 하기로 된 군중중에서 선택되는 화합물. 5-[(6-메톡시-2-벤조푸라닐)메틸렌]-2-티옥소-4-티아졸리디논, 5-[(5-메톡시-2-벤조푸라닐)메틸렌]-2-티옥소-4-티아졸리디논,5-(벤조[b]티엔-2-일메틸렌-로다닌, 5-[(5-메톡시-3-(1-메틸에톡시)벤조[b]티엔-2-일]메틸렌]-2-티옥소-4-티아졸리디논 및 5-[(5-메톡시-1-페닐-1H-인돌-2-일)메틸렌]-2-티옥소-4-티아졸리디논,
  72. 5-[(3,5-비스(1,1-디메틸에틸)-4-히드록시페닐)메틸렌]-2,4-티아졸리디논, 콜린염.
  73. 5-[(3,5-비스(1,1-디메틸에틸)-4-히드록시페닐)메틸렌]-2-티옥소-4-옥사졸리디논, 콜린염.
  74. 의학적 치료제의 제조에 있어서, 제약상 허용되는 담체와 하기 일반식(Ⅰ)의 화합물 및 제약상 허용되는 이들의 염의 용도.
    식중, Ar은 (ⅰ)페닐기, (ⅱ)저급 알킬, 저급 알콕시, 히드록시, 할로겐, 트리플루오로메틸, NO2, 메르캅토 또는 저급 알킬티오 HR4R5기(여기에서, R4및 R5은 독립적으로 수소 또는 저급 알킬기임)중에서 선택되는 1내지 3개의 기로 치환된 페닐기, (ⅲ)니프틸기, (ⅳ)벤조푸라닐기, (ⅴ)벤조티오페닐기, (ⅵ)티에닐기, (ⅶ)인돌릴기, (ⅷ)푸라닐기, (ⅸ)피리딜기이고, Y 및 Y1은산소 원자 또는 황원자이며, X는 황 원자, 산소 원자, NH 또는 NCH3기이고,X1은 NH 또는 NCH3기이되, 단 Ar은 3,5-디(이소프로필)-4-히드록시페닐기가 아니고, 또한 X1=NH, X=S, Y=S이면, Ar은 3,5-디(t-부틸기)-4-히드록시페닐기가 아니다.
  75. 비스테로이드계 소염제, 말초성진통제, 시클로옥시게나제 억제제, 루토크리엔(leukotiene)길항질, 항히스타민제, 프로스타글란딘 길항질 또는 트롬복산 길항질과 같은 제2의 유효 성분이 추가로 함유된 제1항의 제약 조성물.
    ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019890007006A 1988-05-25 1989-05-25 항알레르기제 및 소염제로서 유용한 티아졸리디논, 이미다졸리디논 및 옥사졸리디논의 아릴메틸레닐 유도체 Expired - Fee Related KR970002228B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19852888A 1988-05-25 1988-05-25
US198,528 1988-05-25
US33434689A 1989-04-10 1989-04-10
US334,346 1989-04-10

Publications (2)

Publication Number Publication Date
KR900018043A true KR900018043A (ko) 1990-12-20
KR970002228B1 KR970002228B1 (ko) 1997-02-26

Family

ID=26893869

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890007006A Expired - Fee Related KR970002228B1 (ko) 1988-05-25 1989-05-25 항알레르기제 및 소염제로서 유용한 티아졸리디논, 이미다졸리디논 및 옥사졸리디논의 아릴메틸레닐 유도체

Country Status (13)

Country Link
EP (2) EP0565135A1 (ko)
JP (1) JP2899309B2 (ko)
KR (1) KR970002228B1 (ko)
AU (1) AU626863B2 (ko)
CA (1) CA1340247C (ko)
DE (1) DE68914029T2 (ko)
DK (1) DK252089A (ko)
ES (1) ES2063073T3 (ko)
FI (1) FI892522A7 (ko)
IE (2) IE940525L (ko)
NO (1) NO892083L (ko)
NZ (1) NZ229266A (ko)
PT (1) PT90662B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100844131B1 (ko) * 2007-01-03 2008-07-04 한국화학연구원 로다닌계 화합물 또는 이의 약제학적으로 허용가능한 염을함유하는 항암제

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691367A (en) * 1985-08-09 1997-11-25 Eli Lilly And Company Aryl-substituted rhodanine derivatives
US5356917A (en) * 1985-08-09 1994-10-18 Eli Lilly And Company Aryl-substituted rhodanine derivatives
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US5306822A (en) * 1988-05-25 1994-04-26 Warner-Lambert Company Arylmethylenyl derivatives of oxazolidinone
DE3841879A1 (de) * 1988-12-13 1990-06-21 Boehringer Mannheim Gmbh Neue imidazolidin-derivate, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
ZA902520B (en) * 1989-04-07 1991-12-24 Lilly Co Eli Aryl-substituted rhodanine derivatives
US5216002A (en) * 1989-12-21 1993-06-01 Eli Lilly And Company Method of treating inflammatory bowel disease
IL96654A (en) * 1989-12-21 1995-06-29 Lilly Co Eli Hydroxybenzyl substituted sulfur containing heterocyclic derivatives their preparation and pharmaceutical compositions containing them
DK0514452T4 (da) * 1990-02-09 2000-09-18 Upjohn Co Anvendelse af insulin-sensibiliserende midler til behandling af hypertension
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
EP0526598B1 (en) * 1990-04-27 1996-12-18 Orion-Yhtymà„ Oy New pharmacologically active catechol derivatives
US5158966A (en) * 1991-02-22 1992-10-27 The University Of Colorado Foundation, Inc. Method of treating type i diabetes
US5143927A (en) * 1991-05-09 1992-09-01 Warner-Lambert Company 3-(thiazolidone, oxazolidinone, imidazolidinone)-indoles as antiinflammatory agents
EP0545478A1 (en) * 1991-12-03 1993-06-09 MERCK SHARP & DOHME LTD. Heterocyclic compounds as tachykinin antagonists
CZ181493A3 (en) * 1992-09-10 1994-03-16 Lilly Co Eli The use of rhodanine derivative for the preparation of a pharmaceutical composition reducing level of sugar in blood and for treating alzheimer's disease
US5408009A (en) * 1992-11-02 1995-04-18 Fuji Photo Film Co., Ltd. High polymer-nonlinear optical material
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US6251928B1 (en) * 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
AU735590B2 (en) * 1994-06-24 2001-07-12 Euro-Celtique S.A. Compounds for and method of inhibiting phosphodiesterase IV
CA2193725A1 (en) * 1994-06-24 1996-01-04 David Cavalla Aryl derivative compounds and uses to inhibit phosphodiesterase iv acti vity
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US6025361A (en) * 1994-12-13 2000-02-15 Euro-Celtique, S.A. Trisubstituted thioxanthines
EP0814809B1 (en) 1994-12-13 2003-08-13 Euroceltique S.A. Aryl thioxanthines
JP2001523213A (ja) 1994-12-13 2001-11-20 ユーロ−セルティーク，エス．エイ． 三置換チオキサンチン類
US5563277A (en) * 1994-12-21 1996-10-08 Eli Lilly And Company Process for preparing benzyl-substituted rhodanine derivatives
MX9705557A (es) * 1995-01-23 1997-10-31 Lilly Co Eli Metodo y composiciones para el tratamiento de la esclerosis multiple.
IL117208A0 (en) * 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5864037A (en) * 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5744473A (en) * 1996-09-16 1998-04-28 Euro-Celtique, S.A. PDE IV inhibitors: "bis-compounds"
US6423708B1 (en) 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
UA56185C2 (uk) 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
USRE38132E1 (en) 1997-03-03 2003-06-03 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines,3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
SK117499A3 (en) * 1997-03-03 2000-05-16 Boehringer Ingelheim Pharma Small molecules useful in the treatment of inflammatory and immune cell-mediated diseases, small molecules and pharmaceutical composition with their content
US6355664B1 (en) 1997-03-03 2002-03-12 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
US6673816B1 (en) 1998-09-30 2004-01-06 Angelika Esswein Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders
WO2000018745A1 (en) * 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Oxazolidine derivatives for the treatment and prevention of metabolic bone disorders
WO2000018748A1 (en) * 1998-09-30 2000-04-06 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
AU6340600A (en) * 1999-07-01 2001-01-22 Geron Corporation Telomerase inhibitors and methods of their use
US6492408B1 (en) 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
JP3833532B2 (ja) 1999-07-21 2006-10-11 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 炎症性疾患の治療において有用な小分子
WO2001007044A1 (en) 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
WO2001007052A1 (en) 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
BR0013671A (pt) 1999-08-31 2003-06-10 Maxia Pharmaceuticals Inc Derivados heterocìclicos para o tratamento do diabetes e outras doenças
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
WO2002072009A2 (en) 2001-03-07 2002-09-19 Maxia Pharmaceuticals, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
JP2004523571A (ja) 2001-03-08 2004-08-05 マキシア・ファーマシューティカルズ・インコーポレイテッド Ｒｘｒ活性化分子
EP1456187A4 (en) 2001-11-15 2005-02-09 Incyte San Diego Inc N-SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF HYPERCHOLESTERINEMIA, DYSLIPIDEMIA AND OTHER METABOLIC DISORDER, CANCER AND OTHER DISEASES
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
AU2003291024A1 (en) * 2002-11-13 2004-06-03 Rigel Pharmaceuticals, Inc. Rhodanine derivatives and pharmaceutical compositions containing them
DK2384753T3 (en) 2003-08-29 2016-04-11 Brigham & Womens Hospital Hydantoin derivatives as inhibitors of cell necrosis
FR2919608B1 (fr) * 2007-08-01 2012-10-05 Univ Rennes Derives d'imidazolones,procede de preparation et applications biologiques
PT2225238E (pt) 2007-11-29 2014-12-18 Boehringer Ingelheim Int Derivados de amidas do ácido 6,7-di-hidro-5h-imidazo[1,2- a]imidazol-3-carboxílico
UY31952A (es) * 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
BRPI0923126A2 (pt) 2008-12-23 2021-09-08 President And Fellows Of Harvard College Compostos inibidores de molécula pequena de necroptose, uso e composição compreendendo os mesmos e método de diminuir necroptose
EP2445914B1 (en) 2009-06-02 2015-07-22 Boehringer Ingelheim International GmbH DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
US8575360B2 (en) 2009-06-02 2013-11-05 Boehringer Ingelheim International Gmbh Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-carboxylic acid amides
JP5893571B2 (ja) * 2011-01-27 2016-03-23 保土谷化学工業株式会社 電荷制御剤及びそれを用いたトナー
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
EP2801573A1 (en) * 2013-05-09 2014-11-12 Sanofi Hydantoine derivatives as CD38 inhibitors
WO2016077793A1 (en) * 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment
WO2016094846A1 (en) 2014-12-11 2016-06-16 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
KR101699659B1 (ko) * 2016-01-26 2017-01-24 부산대학교 산학협력단 (ｚ)―５―(４―히드록시―３，５―디메톡시벤질리덴)―２―티옥소이미다졸리딘―４―온)을 유효성분으로 포함하는 암 예방 또는 치료용 조성물
CN109475565B (zh) * 2016-04-05 2021-11-02 免疫传感器公司 cGAS拮抗剂化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1038050B (de) * 1955-11-17 1958-09-04 Farmaceutici Italia S A Soc Verfahren zur Herstellung von 5-(3', 4'-Dioxybenzyliden)-Derivaten heterocyclischer Verbindungen
GB1439318A (en) * 1972-06-16 1976-06-16 Canada Packers Ltd 5-substituted benzal- hydantoins derivatives
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
DE3023349A1 (de) * 1980-06-21 1982-01-14 Degussa Ag, 6000 Frankfurt Verfahren zur herstellung von 5-arylidenhydantoinen (c)
US4431656A (en) * 1981-02-05 1984-02-14 Kanegafuchi Chemical Industry Company Limited 3,5-di-Tert-butylstyrene derivatives, salts thereof, and pharmaceutical compositions containing the same as an active ingredient
GR862081B (en) * 1985-08-09 1986-12-24 Lilly Co Eli Di-t-butylphenol compounds
AU2484288A (en) * 1987-09-29 1989-04-18 Taiho Pharmaceutical Co., Ltd. Thiohydantoin compounds
DE3841879A1 (de) * 1988-12-13 1990-06-21 Boehringer Mannheim Gmbh Neue imidazolidin-derivate, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100844131B1 (ko) * 2007-01-03 2008-07-04 한국화학연구원 로다닌계 화합물 또는 이의 약제학적으로 허용가능한 염을함유하는 항암제

Also Published As

Publication number Publication date
JP2899309B2 (ja) 1999-06-02
KR970002228B1 (ko) 1997-02-26
NZ229266A (en) 1991-12-23
IE891499L (en) 1989-11-25
DE68914029T2 (de) 1994-07-07
AU626863B2 (en) 1992-08-13
EP0565135A1 (en) 1993-10-13
EP0343643A3 (en) 1990-03-21
IE62214B1 (en) 1995-01-11
EP0343643A2 (en) 1989-11-29
NO892083L (no) 1989-11-27
FI892522A7 (fi) 1989-11-26
AU3505889A (en) 1989-11-30
JPH0262864A (ja) 1990-03-02
PT90662B (pt) 1994-10-31
IE940525L (en) 1989-11-25
EP0343643B1 (en) 1994-03-23
ES2063073T3 (es) 1995-01-01
PT90662A (pt) 1989-11-30
DK252089A (da) 1989-11-26
CA1340247C (en) 1998-12-15
DK252089D0 (da) 1989-05-24
NO892083D0 (no) 1989-05-24
DE68914029D1 (de) 1994-04-28
FI892522A0 (fi) 1989-05-24

Similar Documents

Publication Publication Date Title
NZ229266A (en) Compositions containing arylmethylene-substituted thiazolidinone, imidazolidinone and oxazolidinone derivatives and sulphur analogues (thiones)
JP2009520686A5 (ko)
RU96100763A (ru) Фенильные гетероциклы как ингибиторы циклооксигеназы-2
RU2190425C2 (ru) Способ и композиция для лечения и предупреждения гиперурикемии
RU2402553C2 (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛ-ПИРИМИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ mGluR2
RU2006142552A (ru) Производные амино-5,5-дифенилимидазолона как ингибиторы b-секретазы
WO2001024796A1 (en) 1,2,4-triazole derivatives, composition, process of making and methods of use
RU2006121651A (ru) Производные 5-(бенз-(z)-илиден)тиазолидин-4-она в качестве иммуносупрессорных агентов
KR880007411A (ko) 레티논산과 같은 작용을 갖는 에티닐헤테로 방향족-산류
KR960017648A (ko) 옥사졸리딘디온 유도체, 그의 제법 및 용도
CA2636826A1 (en) Thiazoles as 11 beta-hsd1 inhibitors
RU2001127082A (ru) Производные аминов
PT1007039E (pt) Novos analogos heterociclicos de compostos de difeniletileno
JP2006516251A5 (ko)
RU2008138163A (ru) 4-фенилтиазол-5-карбоновые кислоты и амиды 4-фенилтиазол-5-карбоновой кислоты как ингибиторы polo-подобной киназы plk1
KR920009396A (ko) 5-리폭시게나제 억제제 및 시클로옥시게나제 억제제를 포함하는 상승제
KR950701328A (ko) 메일라드 반응 억제제로서의 티아졸 또는 이미다졸 유도체(Thiazole or imidazole derivatives as Maillard reaction inhibitors)
KR890000477A (ko) 신규 화합물들
DE3763630D1 (de) 1h,3h-pyrrolo(1,2-c)thiazolderivate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen.
ZA200404544B (en) Use of endothelin receptor antagonists in the treatment of tumour diseases.
JP2005519878A5 (ko)
RU2005116243A (ru) Новые соединения и их применение в качестве ppar-модуляторов
RU2001111323A (ru) Производные 2-фенилпиран-4-она
KR920703040A (ko) 진경 특성 및 신경보호특성을 갖는 아릴알킬-아민 및-아미드
RU99105208A (ru) Фармацевтическая композиция, содержащая 4-оксобутановые кислоты

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20030711

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20040812

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20040812

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000